Cargando…

Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients

OBJECTIVES: Teriflunomide, a disease‐modifying treatment approved for multiple sclerosis (MS), inhibits reversibly dihydroorotate dehydrogenase, an enzyme involved in de novo pyrimidine biosynthesis and down‐regulates proliferation of activated lymphocytes. We aimed to study the impact of this drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Medina, Silvia, Sainz de la Maza, Susana, Villarrubia, Noelia, Álvarez‐Lafuente, Roberto, Costa‐Frossard, Lucienne, Arroyo, Rafael, Monreal, Enric, Tejeda‐Velarde, Amalia, Rodríguez‐Martín, Eulalia, Roldán, Ernesto, Álvarez‐Cermeño, José C., Villar, Luisa M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389853/ https://www.ncbi.nlm.nih.gov/pubmed/30847367 http://dx.doi.org/10.1002/acn3.711

Ejemplares similares

Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis
por: Picón, Carmen, et al.
Publicado: (2021)

Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome
por: Monreal, Enric, et al.
Publicado: (2021)

Teriflunomide and Epstein–Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response
por: Domínguez-Mozo, María Inmaculada, et al.
Publicado: (2023)

Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
por: Walo-Delgado, Paulette Esperanza, et al.
Publicado: (2021)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab
por: Walo-Delgado, Paulette Esperanza, et al.
Publicado: (2021)

Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis
por: Monreal, Enric, et al.
Publicado: (2023)

Anti-Human Herpesvirus 6 A/B Antibodies Titers Correlate With Multiple Sclerosis-Associated Retrovirus Envelope Expression
por: Pérez-Pérez, Silvia, et al.
Publicado: (2021)

Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine
por: Rodero-Romero, Alexander, et al.
Publicado: (2023)

Acetate correlates with disability and immune response in multiple sclerosis
por: Pérez-Pérez, Silvia, et al.
Publicado: (2020)

Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies
por: Sainz de la Maza, Susana, et al.
Publicado: (2023)

Mitochondrial Impairments in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients
por: Domínguez-Mozo, María Inmaculada, et al.
Publicado: (2022)

Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab
por: Dominguez-Mozo, Maria Inmaculada, et al.
Publicado: (2020)

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
por: Fernández-Velasco, José I., et al.
Publicado: (2021)

Comparative Diagnostic Accuracy of Ganglion Cell-Inner Plexiform and Retinal Nerve Fiber Layer Thickness Measures by Cirrus and Spectralis Optical Coherence Tomography in Relapsing-Remitting Multiple Sclerosis
por: González-López, Julio J., et al.
Publicado: (2014)

Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls
por: Dominguez-Mozo, Maria Inmaculada, et al.
Publicado: (2021)

Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
por: Fernández-Velasco, José I., et al.
Publicado: (2022)

High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study
por: Monreal, Enric, et al.
Publicado: (2020)

An update of teriflunomide for treatment of multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2013)

Teriflunomide promotes oligodendroglial differentiation and myelination
por: Göttle, Peter, et al.
Publicado: (2018)

Teriflunomide: Lack of efficacy: case report
Publicado: (2022)

Lichenoid Drug Eruption Induced by Teriflunomide
por: Agharbi, Fatima-Zahra, et al.
Publicado: (2023)

Painful Small Fiber Neuropathy Associated With Teriflunomide: A Case Series and Literature Review Related to Teriflunomide and Leflunomide
por: Elrefaey, Ahmed, et al.
Publicado: (2023)

Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report
por: Ferreira, Cristiane Munaretto, et al.
Publicado: (2021)

Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis
por: Fissolo, Nicolás, et al.
Publicado: (2022)

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2014)

Role of oral teriflunomide in the management of multiple sclerosis
por: Tanasescu, Radu, et al.
Publicado: (2013)

Teriflunomide as a therapeutic means for myelin repair
por: Göttle, Peter, et al.
Publicado: (2023)

Neuropathy in multiple sclerosis patients treated with teriflunomide
por: Kilic, Ahmet Kasim, et al.
Publicado: (2023)

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
por: Freedman, Mark S, et al.
Publicado: (2017)

Metabolomic signatures associated with disease severity in multiple sclerosis
por: Villoslada, Pablo, et al.
Publicado: (2017)

Tolerogenic therapies in transplantation
por: Page, Eugenia K., et al.
Publicado: (2012)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

Teriflunomide treatment reduces B cells in patients with MS
por: Gandoglia, Ilaria, et al.
Publicado: (2017)

Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity
por: Ambrosius, Björn, et al.
Publicado: (2017)

COVID-19 in teriflunomide-treated patients with multiple sclerosis
por: Maghzi, Amir Hadi, et al.
Publicado: (2020)

Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2020)

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
por: Tornatore, Carlo, et al.
Publicado: (2022)

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
por: Cohan, Stanley L, et al.
Publicado: (2019)

The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19
por: Monreal, Enric, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rsri2vqjrbelvnj6bt8800kma1